| abstract |
The technical field of the invention relates to stable solid dosage forms of amlodipine besylate and benazepril hydrochloride; and processes for their preparation. In particular, the solid dosage forms having reduced levels of 3-ethyl methyl [(2- aminoethoxy) methyl] (2-chlorophenyl) methylpyridine-3,5 dicarboxylate ('impurity D') and total impurities when free of dicalcium phosphate. |